ARTL ARTELO BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1621221 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.4%
TTM EPS YoY188.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-404.2%
ROA-206.9%
ROIC (approx.)-398.3%
Asset turnover—
Leverage & solvency
Liabilities / assets6.6%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-83.52x
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio8.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20222021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $5.42M | $5.99M | $5.70M | $4.32M | $3.78M |
| SG&A expense | $5.98M | $4.12M | $4.23M | $5.96M | $5.63M |
| Operating income | -$11.40M | -$10.11M | -$9.93M | -$10.29M | -$9.42M |
| Interest expense | $194,000 | $0 | $0 | $5,000 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.88M | -$9.83M | -$9.29M | -$10.08M | -$9.41M |
| EPS (diluted) | -12.52 | -18.30 | -3.14 | — | — |
| Weighted avg. shares (diluted) | 1.03M | 537,000 | 2.96M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $600,000 | $2.34M | $2.81M | $6.89M | $12.16M |
| Short-term investments | — | $0 | $7.61M | $9.15M | $11.95M |
| Current assets | $695,000 | $2.56M | $10.98M | $18.32M | $24.61M |
| Intangibles | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M |
| Total assets | $2.80M | $4.70M | $13.04M | $20.42M | $28.25M |
| Current liabilities | $4.04M | $1.77M | $1.29M | $998,000 | $1.03M |
| Total liabilities | $4.07M | $1.84M | $1.29M | $1.02M | $1.08M |
| Shareholders' equity | -$1.27M | $2.86M | $11.75M | $19.40M | $27.17M |
| Shares outstanding | 74,779 | 567,582 | 3.19M | 2.86M | 2.82M |
| Cash flow statement | |||||
| Operating cash flow | -$8.52M | -$8.35M | -$8.21M | -$8.01M | — |
| Investing cash flow | -$62,000 | $7.77M | $3.51M | $2.96M | — |
| Financing cash flow | $6.87M | $112,000 | $567,000 | $0 | — |
| Stock-based compensation | $1.14M | $818,000 | $1.02M | $2.46M | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.